Article Text

other Versions

Download PDFPDF
Original article
Prevalence of human papillomavirus-related diseases in the Republic of Korea: a cross-sectional study
  1. Jin-Kyoung Oh1,2,
  2. Hwa Young Choi1,3,
  3. Minji Han1,
  4. Jae-Kwan Lee4,
  5. Kyung-Jin Min4,
  6. Moran Ki1
  1. 1 Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea
  2. 2 Cancer Risk Appraisal and Prevention Branch, National Cancer Center, Goyang, Republic of Korea
  3. 3 Graduate School of Public Health, Hanyang University, Seoul, Republic of Korea
  4. 4 Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Republic of Korea
  1. Correspondence to Dr Moran Ki, Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 410-769, Republic of Korea; moranki{at}ncc.re.kr

Abstract

Objective We aimed to evaluate trends in the prevalence of human papillomavirus (HPV)-related diseases in the era before the introduction of organised HPV vaccination programmes in the Republic of Korea.

Methods This cross-sectional study used National Health Insurance Service data from 2002 to 2015 and included participants who were diagnosed with the following HPV-related diseases (codes from the International Classification of Diseases, 10th Revision): genital warts (A63.0); cancer in the head and neck (C00–C10), anus (C21), vulva (C51), vagina (C52), cervix uteri (C53) and penis (C60); carcinoma in situ (CIS) of the lip/oral cavity/pharynx (D00.0), anus (D01.3), cervix (D06), vulva (D07.1), vagina (D07.2) and penis (D07.4); benign neoplasms of the larynx (D14.1); and dysplasia of the cervix (N87), vagina (N89) and vulva (N90). For each diagnosis, the fraction of cases attributable to HPV in Korea was assessed based on the percentages of diseases attributable to HPV reported in some international studies. The age-standardised prevalence was estimated using the direct population-based method.

Results The overall age-standardised prevalence of HPV-related diseases increased from 2002 to 2015, mainly due to increased prevalence of genital warts in men and cervical dysplasia and CIS in women. In women, genital wart prevalence increased from 2002 (24.4 per 100 000) to 2011 (57.1) and then decreased until 2015 (53.5); in men, the prevalence increased steadily from 2002 (22.9) to 2015 (109.4). The prevalence of cervical dysplasia and CIS increased (from 86.5 in 2002 to 484.5 in 2015, and from 60.3 in 2002 to 114.9 in 2015, respectively), but that of cervical cancer decreased (from 120.0 in 2002 to 106.9 in 2015).

Conclusions Non-organised HPV vaccination and organised cervical cancer screening may have contributed to the downward trend in genital wart prevalence and the upward trend in cervical abnormalities among women.

  • human papillomavirus
  • cancer
  • vaccination
  • cervical cancer
  • genital warts
  • head and neck cancer

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • J-KO and HYC contributed equally.

  • Handling editor Nigel Field

  • Contributors Conceptualisation: JKO, MK and JKL. Methodology: JKO, MK and HYC. Formal analysis: HYC. Investigation: JKO, MK, HYC and MH. Writing–original draft preparation: JKO, HYC and MH. Writing–review and editing: JKO, MK, JKL and KJM. Funding acquisition: JKL, JKO and MK. Supervision: MK.

  • Funding This work was supported by the Centers for Disease Control and Prevention of Korea (grant number 2016E3200600) and partly supported by the National Cancer Center (NCC-1610410; NCC-1710141-1).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Institutional Review Board of Korea University Guro Hospital (approval number KUGH16216-001).

  • Provenance and peer review Not commissioned; externally peer reviewed.